ÂÜÀòÂÒÂ×

Stephan Christgau is an experienced leader in the biotechnology and venture capital sectors, currently serving as Chairperson at GutCRINE ApS and Henlez, with Henlez focused on developing innovative therapies for Hidradenitis suppurativa. Additionally, Christgau holds the position of Director at Scenic Biotech, a company utilizing genetic modifier technology for novel therapies. As a Founding Partner at Eir Ventures, a life sciences venture fund, Christgau invests in promising opportunities in the Nordic Biotech ecosystem. Other significant roles include Chairperson at Octarine and Chairman of the Board at Venture Cup, a prominent non-profit organization in Scandinavia. Christgau has also contributed as a Board Member for various biotech firms, including ISD-Immunotech and Galecto Biotech. Academic qualifications include degrees from DTU, University of California, San Francisco, and Harvard Business School.